| Author/Institution |
# |
Tumor Site (#) |
Histology |
RT Type (# pt) |
Dose in CGE |
5y-LC (%) |
5y-OS (%) |
F/U in months (range) |
| Benk (MGH)[49] |
18 |
SB (15)
C-spine (3) |
All CH |
P + Ph (18) |
Median, 69.0 |
63% |
68%* |
Median, 72 (19-120) |
| Habrand (CPO)[50] |
30 |
SB (16)
C-spine (1)
Both (13) |
27 CH
3 CS |
P + Ph (29)
P (1) |
Mean, 69.1
Mean, 65.3 |
77% (CH)
100% (CS) |
81% (CH)
100% (CS) |
Mean, 26.5 (5-102) |
| Hug (LLUMC)[51] |
13 |
SB |
10 CH
3 CS |
P (6)
P + Ph (4)
P + Ph (3) |
Median, 73.7
Median, 70.0 |
60% (CH) §
100% (CS) § |
60% (CH)**
100% (CS) § |
Mean, 40 (13-92) |
| Rombi (PSI)[52] |
26 |
SB (17)
Axial Skel (9) |
19 CH
7 CS |
P (All) |
Mean, 74.0
Mean, 66.0 |
81%(CH)
80% (CS) |
89% (CH)
75% (CS) |
Mean, 46 (5-126) |
*: patients with cervical spine chordoma had a significant worse survival than other skull base patients (p= 0.008);
**: overall survival of the males was significantly superior to female patients (p=0.002);
§ :at last follow up
Abbreviations:
#: number of; RT: radiotherapy; pt: patients; LC: local control; OS: overall survival; F/U: follow up; SB: skull base; CH: chordoma; CS: chondrosarcoma;
Skel: skeleton; P: protons; Ph: photons; y: year. |
